Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition
Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …
Co-delivery anticancer drug nanoparticles for synergistic therapy against lung cancer cells
Y Shen, J TanTai - Drug Design, Development and Therapy, 2020 - Taylor & Francis
Introduction This study aims to develop a novel co-delivery gefitinib and quercetin system
loaded with PLGA-PEG nanoparticles and evaluate their antitumor activity in vitro and in …
loaded with PLGA-PEG nanoparticles and evaluate their antitumor activity in vitro and in …
Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
Biodegradable nanoparticles mediated co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer …
D Chen, F Zhang, J Wang, H He, S Duan… - Frontiers in …, 2018 - frontiersin.org
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo
S Tan, G Wang - Drug Design, Development and Therapy, 2017 - Taylor & Francis
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …
Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …
Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis
JT Long, T Cheang, SY Zhuo, RF Zeng, QS Dai… - Journal of …, 2014 - Springer
Background Inhalation of chemotherapeutic drugs directly into the lungs augments the drug
exposure to lung cancers. The inhalation of free drugs however results in over exposure and …
exposure to lung cancers. The inhalation of free drugs however results in over exposure and …
Development and in vitro evaluation of core–shell type lipid–polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer
B Mandal, NK Mittal, P Balabathula, LA Thoma… - European journal of …, 2016 - Elsevier
Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …
multifunctional drug delivery platform. The delivery system combines mechanical …
Delivery of gefitinib in synergism with thymoquinone via transferrin-conjugated nanoparticle sensitizes gefitinib-resistant non-small cell lung carcinoma to control …
P Upadhyay, A Ghosh, A Basu, PA Pranati… - Biomaterials …, 2021 - pubs.rsc.org
Epidermal growth factor receptor (EGFR) normally over-expresses in non-small cell lung
cancer (NSCLC) cells. Its mutations act as oncogenic drivers in the cellular signal …
cancer (NSCLC) cells. Its mutations act as oncogenic drivers in the cellular signal …
Aptamer-conjugated chitosan-anchored liposomal complexes for targeted delivery of erlotinib to EGFR-mutated lung cancer cells
F Li, H Mei, X Xie, H Zhang, J Liu, T Lv, H Nie, Y Gao… - The AAPS journal, 2017 - Springer
Lung cancer is the leading cancer and has the highest death rate. The epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has had a promising response …
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has had a promising response …